PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3499607-1 1987 The human bladder carcinoma cell line 5637 produces hematopoietic growth factors [granulocyte and granulocyte/macrophage colony-stimulating factors (G-CSF and GM-CSF)] and hemopoietin 1, which synergizes with CSFs to stimulate colony formation by primitive hematopoietic stem cells in 5-fluorouracil-treated mouse bone marrow. Fluorouracil 285-299 colony stimulating factor 2 Homo sapiens 159-185 2473792-3 1989 Cultures of unseparated bone marrow, harvested from patients four to six days after administration of 5-fluorouracil (5-FU), resulted in additive GM colony formation with GM-CSF plus G-CSF, GM-CSF plus IL-3, and G-CSF plus IL-3. Fluorouracil 118-122 colony stimulating factor 2 Homo sapiens 171-177 2473792-3 1989 Cultures of unseparated bone marrow, harvested from patients four to six days after administration of 5-fluorouracil (5-FU), resulted in additive GM colony formation with GM-CSF plus G-CSF, GM-CSF plus IL-3, and G-CSF plus IL-3. Fluorouracil 118-122 colony stimulating factor 2 Homo sapiens 190-196 25432336-4 2015 Interestingly, cell viability studies showed pronounced sensitivity of GMCSF overexpressing MCF-7 cells towards anticancer drugs, such as, doxorubicin, 5FU and cisplatin. Fluorouracil 152-155 colony stimulating factor 2 Homo sapiens 71-76 2947416-0 1986 Passage of 5"-dFUrd and its metabolites 5-FU and 5-FUH2 to CSF in a clinical phase 1 study. Fluorouracil 40-44 colony stimulating factor 2 Homo sapiens 59-62 2947416-2 1986 5"-dFUrd, 5"FU, and 5-FUH2 were shown to cross the blood-brain barrier to CSF. Fluorouracil 10-14 colony stimulating factor 2 Homo sapiens 74-77 6426399-6 1984 2) The level of 5-FU concentration in CSF had been kept highly very longer time, compared with that of in plasma. Fluorouracil 16-20 colony stimulating factor 2 Homo sapiens 38-41 6426399-8 1984 3) About 0,05 mcg/ml of 5-FU in CSF would be maintained for 24 hours in patients following administration of FT-207 suppository (1 g, daily) for 3 days or more. Fluorouracil 24-28 colony stimulating factor 2 Homo sapiens 32-35 7826903-13 1994 A modest increase in FLAC dose intensity over the starting doses was achievable with the addition of GM-CSF. Fluorouracil 21-25 colony stimulating factor 2 Homo sapiens 101-107 23449328-0 2013 Effect of rice cell-derived human granulocyte-macrophage colony-stimulating factor on 5-fluorouracil-induced mucositis in hamsters. Fluorouracil 86-100 colony stimulating factor 2 Homo sapiens 34-82 19110579-3 2008 Under conditions of 5-fluorouracil treatment, the effect of the adrenergic system was aimed at the formation of granulocytic and fibroblast-type cell complexes, activation of the production of colony-forming activity by microenvironmental cells, and acceleration of maturation of neutrophilic granulocytes associated with the system of granulocytic CSF and peripheral alpha-adrenergic structures. Fluorouracil 20-34 colony stimulating factor 2 Homo sapiens 349-352 10499610-0 1999 A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma. Fluorouracil 38-50 colony stimulating factor 2 Homo sapiens 78-126 10499610-1 1999 We reported previously that the addition of recombinant Escherichia coli human granulocyte-macrophage colony stimulating factor (GM-CSF) to a 5-fluorouracil (5-FU) and leucovorin (LV) regimen seemed to ameliorate diarrhea and permit increased 5-FU dose intensity (J. L. Grem et al., J. Clin. Fluorouracil 142-156 colony stimulating factor 2 Homo sapiens 79-127 10499610-1 1999 We reported previously that the addition of recombinant Escherichia coli human granulocyte-macrophage colony stimulating factor (GM-CSF) to a 5-fluorouracil (5-FU) and leucovorin (LV) regimen seemed to ameliorate diarrhea and permit increased 5-FU dose intensity (J. L. Grem et al., J. Clin. Fluorouracil 142-156 colony stimulating factor 2 Homo sapiens 129-135 10499610-1 1999 We reported previously that the addition of recombinant Escherichia coli human granulocyte-macrophage colony stimulating factor (GM-CSF) to a 5-fluorouracil (5-FU) and leucovorin (LV) regimen seemed to ameliorate diarrhea and permit increased 5-FU dose intensity (J. L. Grem et al., J. Clin. Fluorouracil 158-162 colony stimulating factor 2 Homo sapiens 79-127 10499610-1 1999 We reported previously that the addition of recombinant Escherichia coli human granulocyte-macrophage colony stimulating factor (GM-CSF) to a 5-fluorouracil (5-FU) and leucovorin (LV) regimen seemed to ameliorate diarrhea and permit increased 5-FU dose intensity (J. L. Grem et al., J. Clin. Fluorouracil 243-247 colony stimulating factor 2 Homo sapiens 79-127 10499610-1 1999 We reported previously that the addition of recombinant Escherichia coli human granulocyte-macrophage colony stimulating factor (GM-CSF) to a 5-fluorouracil (5-FU) and leucovorin (LV) regimen seemed to ameliorate diarrhea and permit increased 5-FU dose intensity (J. L. Grem et al., J. Clin. Fluorouracil 243-247 colony stimulating factor 2 Homo sapiens 129-135 10999043-0 1999 Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. Fluorouracil 44-58 colony stimulating factor 2 Homo sapiens 77-125 10999043-11 1999 In a weekly schedule with high-dose LV and GM-CSF, the MTD of 5-FU and 5-FU delivered dose intensity were higher than previously reported with 5-FU and LV administered without GM-CSF. Fluorouracil 62-66 colony stimulating factor 2 Homo sapiens 43-49 10999043-11 1999 In a weekly schedule with high-dose LV and GM-CSF, the MTD of 5-FU and 5-FU delivered dose intensity were higher than previously reported with 5-FU and LV administered without GM-CSF. Fluorouracil 71-75 colony stimulating factor 2 Homo sapiens 43-49 10999043-11 1999 In a weekly schedule with high-dose LV and GM-CSF, the MTD of 5-FU and 5-FU delivered dose intensity were higher than previously reported with 5-FU and LV administered without GM-CSF. Fluorouracil 71-75 colony stimulating factor 2 Homo sapiens 43-49 7579383-6 1995 Sequential IL-3 and GM-CSF (schedule B) was associated with higher platelet nadirs, shorter durations of platelet counts less than 50,000/microL, and the need for fewer platelet transfusions over five cycles of FLAC chemotherapy compared with concurrent cytokines, sequential IL-3 and GM-CSF schedule A, and GM-CSF alone. Fluorouracil 211-215 colony stimulating factor 2 Homo sapiens 20-26 7579383-10 1995 The data from this phase I study suggest that sequential IL-3 and GM-CSF with IL-3 administered for 9 days before beginning GM-CSF may be superior to shorter durations of IL-3 administered sequentially with GM-CSF, to concurrent IL-3 and GM-CSF, and to either colony-stimulating factor alone in ameliorating the cumulative hematologic toxicity associated with multiple cycles of FLAC chemotherapy. Fluorouracil 379-383 colony stimulating factor 2 Homo sapiens 66-72 7534710-3 1995 We also showed that 5-FU-resistant PBSC have a greater capacity for expansion of IL-1/IL-3/SCF-responsive immature progenitors (p = 0.05), amplification of IL-3 plus GM-CSF responsive progenitors (p = 0.01), and production of committed single growth factor-responsive (granulocyte-macrophage colony-stimulating factor [GM-CSF]) precursors (p = 0.01) than the untreated PBSC. Fluorouracil 20-24 colony stimulating factor 2 Homo sapiens 166-172 7534710-3 1995 We also showed that 5-FU-resistant PBSC have a greater capacity for expansion of IL-1/IL-3/SCF-responsive immature progenitors (p = 0.05), amplification of IL-3 plus GM-CSF responsive progenitors (p = 0.01), and production of committed single growth factor-responsive (granulocyte-macrophage colony-stimulating factor [GM-CSF]) precursors (p = 0.01) than the untreated PBSC. Fluorouracil 20-24 colony stimulating factor 2 Homo sapiens 269-317 7534710-3 1995 We also showed that 5-FU-resistant PBSC have a greater capacity for expansion of IL-1/IL-3/SCF-responsive immature progenitors (p = 0.05), amplification of IL-3 plus GM-CSF responsive progenitors (p = 0.01), and production of committed single growth factor-responsive (granulocyte-macrophage colony-stimulating factor [GM-CSF]) precursors (p = 0.01) than the untreated PBSC. Fluorouracil 20-24 colony stimulating factor 2 Homo sapiens 319-325 7977167-10 1994 CONCLUSIONS: Adding GM-CSF to the combination of cisplatin and 5-fluorouracil allowed to increase 5-fluorouracil dose up to 50% over the conventional dosage. Fluorouracil 63-77 colony stimulating factor 2 Homo sapiens 20-26 7977167-10 1994 CONCLUSIONS: Adding GM-CSF to the combination of cisplatin and 5-fluorouracil allowed to increase 5-fluorouracil dose up to 50% over the conventional dosage. Fluorouracil 98-112 colony stimulating factor 2 Homo sapiens 20-26 23749899-10 2013 Regarding GM-CSF and TNF-alpha, we demonstrated an increase in secretion by the primary tumors under low doses of 5-fluorouracil and cisplatin, whereas the metastases showed a sharp drop of GM-CSF and TNF-alpha secretion. Fluorouracil 114-128 colony stimulating factor 2 Homo sapiens 10-16 12759532-0 2003 Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. Fluorouracil 98-112 colony stimulating factor 2 Homo sapiens 13-61 12759532-2 2003 OBJECTIVE: To test the activity of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in patients with colorectal cancer treated with adjuvant 5-fluorouracil (5-FU) plus leucovorin (LV) and suffering from mucositis. Fluorouracil 178-192 colony stimulating factor 2 Homo sapiens 48-96 12759532-2 2003 OBJECTIVE: To test the activity of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in patients with colorectal cancer treated with adjuvant 5-fluorouracil (5-FU) plus leucovorin (LV) and suffering from mucositis. Fluorouracil 178-192 colony stimulating factor 2 Homo sapiens 98-104 12759532-2 2003 OBJECTIVE: To test the activity of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in patients with colorectal cancer treated with adjuvant 5-fluorouracil (5-FU) plus leucovorin (LV) and suffering from mucositis. Fluorouracil 194-198 colony stimulating factor 2 Homo sapiens 48-96 12759532-2 2003 OBJECTIVE: To test the activity of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in patients with colorectal cancer treated with adjuvant 5-fluorouracil (5-FU) plus leucovorin (LV) and suffering from mucositis. Fluorouracil 194-198 colony stimulating factor 2 Homo sapiens 98-104 12759532-13 2003 CONCLUSIONS: The subcutaneous administration of GM-CSF relieved patients from symptoms of 5-FU/LV-induced mucositis with acceptable side effects permitting the maintenance of full-dose chemotherapy. Fluorouracil 90-94 colony stimulating factor 2 Homo sapiens 48-54 12031098-5 2002 Addition of cytokines that augment these functions, mainly granulocyte macrophage-cerebrospinal fluid (GM-CSF), seemed to improve the clinical efficacy as well as chemotherapeutic agents (5-Fu). Fluorouracil 188-192 colony stimulating factor 2 Homo sapiens 103-109 10564261-2 1999 In suspension cultures of lineage-negative (Lin(-)), 5-fluorouracil-resistant bone marrow cells of the transgenic mice, a combination of hGM-CSF and stem cell factor (SCF) induced exponential expansions of mixed colony-forming unit. Fluorouracil 53-67 colony stimulating factor 2 Homo sapiens 137-144 9446257-5 1997 In a randomized study by Ardizzoni et al., the administration of GM-CSF at the dose of 10 micrograms/kg following CEF program (cyclophosphamide, epirubicin and fluorouracil) was effective in reducing from 20 to 16 days the time interval among cycles. Fluorouracil 160-172 colony stimulating factor 2 Homo sapiens 65-71 9446257-8 1997 have observed that 3 micrograms/kg GM-CSF may allow the administration of 425 mg/m2 fluorouracil for five days; Reed et al. Fluorouracil 84-96 colony stimulating factor 2 Homo sapiens 35-41 8630380-1 1996 We conducted a prospective randomized trial to evaluate the ability of the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein, PIXY321, to ameliorate cumulative thrombocytopenia after multiple cycles of 5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide (FLAC) chemotherapy compared with GM-CSF in patients with advanced breast cancer. Fluorouracil 239-253 colony stimulating factor 2 Homo sapiens 75-137 8630380-1 1996 We conducted a prospective randomized trial to evaluate the ability of the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein, PIXY321, to ameliorate cumulative thrombocytopenia after multiple cycles of 5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide (FLAC) chemotherapy compared with GM-CSF in patients with advanced breast cancer. Fluorouracil 239-253 colony stimulating factor 2 Homo sapiens 139-145 8823488-0 1996 Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer. Fluorouracil 142-156 colony stimulating factor 2 Homo sapiens 19-67 8823488-1 1996 To verify whether the association of granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO) would allow both the acceleration and the dose escalation of the cyclophosphamide/epidoxorubicin/5-fluorouracil (CEF) regimen as first-line therapy in advanced breast cancer patients, we conducted a dose-finding study. Fluorouracil 217-231 colony stimulating factor 2 Homo sapiens 37-85 8823488-1 1996 To verify whether the association of granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO) would allow both the acceleration and the dose escalation of the cyclophosphamide/epidoxorubicin/5-fluorouracil (CEF) regimen as first-line therapy in advanced breast cancer patients, we conducted a dose-finding study. Fluorouracil 217-231 colony stimulating factor 2 Homo sapiens 87-93 8823488-11 1996 Increasing the doses of Ctx and Epidx while maintaining a fixed dose of 5-Fu with the support of both EPO and GM-CSF allows safe acceleration and dose escalation of CEF chemotherapy. Fluorouracil 72-76 colony stimulating factor 2 Homo sapiens 110-116 8246030-0 1993 Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. Fluorouracil 179-191 colony stimulating factor 2 Homo sapiens 35-83 8120554-2 1994 PATIENTS AND METHODS: Thirty-seven patients received escalating doses of 5-FU/LCV on days 1 to 5 with subcutaneous GM-CSF either 5 or 10 micrograms/kg/d starting on day 6 or 3 micrograms/kg/d starting on day 1. Fluorouracil 73-77 colony stimulating factor 2 Homo sapiens 115-121 7522897-2 1994 The resulting 5-FU-resistant cells were evaluated for (1) the production of GM-CSF-responsive clonogenic elements (CE), (2) the production of IL-3+GM-CSF-responsive CE, and (3) their self-renewal capacity (production of IL-1+IL-3+SCF-responsive CE). Fluorouracil 14-18 colony stimulating factor 2 Homo sapiens 76-82 7522897-6 1994 We also showed that 5-FU-resistant PBSC have a greater capacity for self-renewal, amplification of IL-3+GM-CSF-responsive progenitors, and the production of committed GM-CSF-responsive progenitors as compared with BM cells, but this did not reach statistical significant. Fluorouracil 20-24 colony stimulating factor 2 Homo sapiens 104-110 7522897-6 1994 We also showed that 5-FU-resistant PBSC have a greater capacity for self-renewal, amplification of IL-3+GM-CSF-responsive progenitors, and the production of committed GM-CSF-responsive progenitors as compared with BM cells, but this did not reach statistical significant. Fluorouracil 20-24 colony stimulating factor 2 Homo sapiens 167-173 8481510-8 1993 In 8 of 10 patients whose marrow was studied before and after 5-FU treatment, the numbers of CFU-C responsive to the combination of GM-CSF and IL-3 was increased 6.15-fold by 5-FU pretreatment. Fluorouracil 62-66 colony stimulating factor 2 Homo sapiens 132-138 8481510-8 1993 In 8 of 10 patients whose marrow was studied before and after 5-FU treatment, the numbers of CFU-C responsive to the combination of GM-CSF and IL-3 was increased 6.15-fold by 5-FU pretreatment. Fluorouracil 175-179 colony stimulating factor 2 Homo sapiens 132-138 2092280-1 1990 Modulation of 5-FU cytotoxicity by GM-CSF. Fluorouracil 14-18 colony stimulating factor 2 Homo sapiens 35-41 1449107-1 1992 A Phase I study was conducted to determine whether the addition of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) to a combined 5-fluorouracil (5-FU) and folinic acid (FA) regimen would allow an escalated starting dose of 5-FU. Fluorouracil 175-179 colony stimulating factor 2 Homo sapiens 85-133 1449107-1 1992 A Phase I study was conducted to determine whether the addition of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) to a combined 5-fluorouracil (5-FU) and folinic acid (FA) regimen would allow an escalated starting dose of 5-FU. Fluorouracil 253-257 colony stimulating factor 2 Homo sapiens 85-133